{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6"},{"groupId":"OG001","value":"68.6"},{"groupId":"OG002","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"SC Preference: Very Strong"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"24.3"},{"groupId":"OG002","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"SC Preference: Fairly Strong"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4"},{"groupId":"OG001","value":"7.1"},{"groupId":"OG002","value":"7.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"SC Preference: Not Very Strong"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5"},{"groupId":"OG001","value":"40.0"},{"groupId":"OG002","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"title":"IV Preference: Very Strong"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1"},{"groupId":"OG001","value":"10.0"},{"groupId":"OG002","value":"8.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"title":"IV Preference: Fairly Strong"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"title":"IV Preference: Not Very Strong"}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"78"}],"units":"Participants"}],"description":"Question 1 of the Patient Preference Questionnaire (PPQ) was as follows: \"All things considered, which method of administration did you prefer?\" The available options for a participant's response were IV, SC, or No preference. In Question 2 of the PPQ, participants who reported a preference for one of the two administration routes in Question 1 of the PPQ were asked to rate the strength of their preference (very strong, fairly strong, not very strong).","groups":[{"description":"In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Participants"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"Modified ITT (mITT) Population; for Question 2 of the PPQ, the number analyzed for the strength of SC or IV preference represents the participants who indicated in their responses to Question 1 of the PPQ that they preferred the SC or IV route of administration, respectively.","reportingStatus":"POSTED","timeFrame":"Cycle 6 Day 1 (each cycle is 21 days)","title":"Percentage of Participants by Responses to the Strength of Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 2 of the Patient Preference Questionnaire (PPQ)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}